…ies in the CLARITY trial (Giovannoni et al. N Engl J Med 2010;362:416-426; free pdf at www.nejm.org/doi/pdf/10.1056/NEJMoa0902533). The study randomized 1326 patients to one of two doses of oral cladribine (3.5 or 5.25 mg/kg cumulative dose over two years) or placebo. There were 10 neoplasms in the cladribine groups (incidence 1.1%) versus 0 in the placebo group. The neoplasms reported were five cases of benign uterine leiomyoma, three cases of ca…

…dose of ocrelizumab. Ocrelizumab was excreted in breast milk in animal studies and women are advised not to breastfeed during treatment. Click on the link to download the Canadian Product Monograph: www.rochecanada.com//content/dam/roche_canada/en_CA/documents/Research/ClinicalTrialsForms/Products/ConsumerInformation/MonographsandPublicAdvisories/Ocrevus/OCREVUS_PM_E.pdf…

…news and information website visited by about 3,000 MS patients per month (www.msology.com). The survey was conducted in English and French in February-March 2017. The number of survey respondents was 387: 85% were female, 85% lived in Canada, and 10% lived in the U.S. Patients were generally older (51.7% were aged 50 years or older; 29.4% were aged 41-50 years). Duration of MS was >10 years for 51.8%; 26.8% had been living with MS for 5 years or…